Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (6): 1644-1649.doi: 10.13481/j.1671-587X.20220634
• Review • Previous Articles Next Articles
Received:
2022-02-10
Online:
2022-11-28
Published:
2022-12-07
CLC Number:
1 | ZHANG N N, ZHANG H, JIANG L Q, et al. A novel method of sacral nerve stimulation for colonic inflammation[J].Neurogastroenterol Motil,2020,32(6): e13825. |
2 | ANSALDO E, FARLEY T K, BELKAID Y. Control of immunity by the microbiota[J]. Annu Rev Immunol, 2021, 39: 449-479. |
3 | HERNÁNDEZ M, CANFORA E E, JOCKEN J W E, et al. The short-chain fatty acid acetate in body weight control and insulin sensitivity[J].Nutrients,2019,11(8): 1943. |
4 | DUDIK B, SEPOVA H K, BILKOVA A. Inflammatory bowel disease: factors involved in pathogenesis[J]. Ceska Slov Farm,2018,67(3):95-100. |
5 | KUSHKEVYCH I, DORDEVIĆ D, KOLLAR P,et al. Hydrogen sulfide as a toxic product in the small-large intestine axis and its role in IBD development[J]. J Clin Med, 2019, 8(7): 1054. |
6 | GEVERS D, KUGATHASAN S, KNIGHTS D,et al. A microbiome foundation for the study of Crohn’s disease[J]. Cell Host Microbe, 2017, 21(3): 301-304. |
7 | BELKAID Y, HAND T W. Role of the microbiota in immunity and inflammation[J]. Cell, 2014, 157(1): 121-141. |
8 | GONZÁLEZ OLMO B M, BUTLER M J, BARRIENTOS R M. Evolution of the human diet and its impact on gut microbiota, immune responses, and brain health[J]. Nutrients, 2021, 13(1): 196. |
9 | MORGAN X C, TICKLE T L, SOKOL H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol, 2012, 13(9): R79. |
10 | MOTTAWEA W, CHIANG C K, MÜHLBAUER M, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease[J]. Nat Commun, 2016, 7: 13419. |
11 | GRACIE D J, HAMLIN P J, FORD A C. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment[J]. Lancet Gastroenterol Hepatol, 2019, 4(8): 632-642. |
12 | SINGH V, KUMAR M, BSAN YEOH, et al. Inhibition of interleukin-10 signaling induces microbiota-dependent chronic colitis in apolipoprotein E deficient mice[J]. Inflamm Bowel Dis, 2016, 22(4): 841-852. |
13 | FRANZOSA E A, SIROTA-MADI A, AVILA-PACHECO J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease[J]. Nat Microbiol, 2019, 4(2): 293-305. |
14 | KIM M J, KIM E, KANG B, et al.Anti-Saccharomyces cerevisiae antibody in pediatric Crohn’s disease patients without mucosal healing is a useful marker of mucosal damage[J]. Gut Liver, 2021, 15(5): 763-770. |
15 | GUGGINO G, MAURO D, RIZZO A, et al. Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis[J]. Arthritis Rheumatol, 2021, 73(7): 1189-1199. |
16 | MUKHOPADHYA I, HANSEN R, MEHARG C,et al.The fungal microbiota of de-novo paediatric inflammatory bowel disease[J]. Microbes Infect, 2015, 17(4): 304-310. |
17 | LIGUORI G, LAMAS B, RICHARD M L, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients[J]. J Crohns Colitis, 2016, 10(3): 296-305. |
18 | SASSON A N, INGRAM R J M, ZHANG Z X, et al. The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease[J]. Lancet Gastroenterol Hepatol, 2021, 6(9): 754-769. |
19 | JAIN U, MVER HEUL A, XIONG S S, et al. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice[J]. Science, 2021, 371(6534): 1154-1159. |
20 | DORON I, MESKO M, LI X V, et al. Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn’s disease[J]. Nat Microbiol, 2021, 6(12): 1493-1504. |
21 | TRUNK K, PELTIER J, LIU Y C, et al. The type Ⅵsecretion system deploys antifungal effectors against microbial competitors[J]. Nat Microbiol, 2018, 3(8): 920-931. |
22 | FILYK H A, OSBORNE L C. The multibiome: the intestinal ecosystem’s influence on immune homeostasis,health, and disease[J]. EBioMedicine, 2016, 13: 46-54. |
23 | LAMAS B, RICHARD M L, LEDUCQ V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands[J]. Nat Med, 2016, 22(6): 598-605. |
24 | COSNES J, GOWER-ROUSSEAU C, SEKSIK P,et al.Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011,140(6):1785-1794. |
25 | XU J Y, YU P C, WU L J, et al. Effect of Trichinella spiralis intervention on TNBS-induced experimental colitis in mice[J].Immunobiology, 2019,224(1): 147-153. |
26 | PANELLI S, EPIS S, COCOCCIONI L, et al. Inflammatory bowel diseases, the hygiene hypothesis and the other side of the microbiota: parasites and fungi[J]. Pharmacol Res, 2020, 159: 104962. |
27 | VARELA E, MANICHANH C, GALLART M, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther, 2013, 38(2): 151-161. |
28 | SOKOL H, PIGNEUR B, WATTERLOT L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients[J]. Proc Natl Acad Sci U S A, 2008, 105(43): 16731-16736. |
29 | YUAN H D, MA Q Q, CUI H Y, et al. How can synergism of traditional medicines benefit from network pharmacology? [J]. Molecules, 2017, 22(7): 1135. |
30 | REYES A, HAYNES M, HANSON N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers[J]. Nature, 2010, 466(7304): 334-338. |
31 | KHARDORI N, STEVAUX C, RIPLEY K. Antibiotics: from the beginning to the future: part 2[J]. Indian J Pediatr, 2020, 87(1): 43-47. |
32 | NORMAN J M, HANDLEY S A, BALDRIDGE M T, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease[J].Cell, 2015,160(3):447-460. |
33 | CLOONEY A G, SUTTON T D S, SHKOPOROV A N, et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease[J]. Cell Host Microbe, 2019, 26(6): 764-778.e5. |
34 | SHKOPOROV A N, CLOONEY A G, SUTTON T D S, et al. The human gut virome is highly diverse, stable, and individual specific[J]. Cell Host Microbe, 2019, 26(4): 527-541.e5. |
35 | DUAN Y, YOUNG R, SCHNABL B. Bacteriophages and their potential for treatment of gastrointestinal diseases[J].Nat Rev Gastroenterol Hepatol,2022,19(2): 135-144. |
36 | ANDREWS C N, GRIFFITHS T A, KAUFMAN J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2011, 34(3): 374-383. |
37 | NISHIDA A, INOUE R, INATOMI O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease[J]. Clin J Gastroenterol, 2018, 11(1): 1-10. |
38 | PITCHER M C, BEATTY E R, CUMMINGS J H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis[J]. Gut, 2000, 46(1): 64-72. |
39 | BUSQUETS D, MAS-DE-XAXARS T, LÓPEZ-SILES M,et al. Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn’s disease[J].J Crohns Colitis,2015,9(10): 899-906. |
40 | FLORIN T H J, WRIGHT J D, JAMBHRUNKAR S D,et al. A well-tolerated and rapidly acting thiopurine for IBD? [J]. Drug Discov Today, 2019, 24(1): 37-41. |
41 | HUANG E Y, INOUE T, LEONE V A, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21(5): 963-972. |
42 | SIPPOLA S, HAIJANEN J, GRÖNROOS J, et al. Effect of oral moxifloxacin vs intravenous ertapenem plus oral levofloxacin for treatment of uncomplicated acute appendicitis: the APPAC II randomized clinical trial[J]. JAMA, 2021, 325(4): 353-362. |
43 | ABENAVOLI L, SCARPELLINI E, COLICA C,et al. Gut microbiota and obesity: a role for probiotics[J]. Nutrients, 2019, 11(11): 2690. |
44 | BUTTERWORTH A D, THOMAS A G, AKOBENG A K. Probiotics for induction of remission in Crohn’s disease[J]. Cochrane Database Syst Rev, 2008, 2008(3): CD006634. |
45 | RACHUL C, MARCON A R, COLLINS B, et al. COVID-19 and ‘immune boosting’ on the Internet: a content analysis of Google search results[J]. BMJ Open, 2020, 10(10): e040989. |
46 | QURAISHI M N, WIDLAK M, BHALA N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection[J]. Aliment Pharmacol Ther, 2017, 46(5): 479-493. |
47 | ANDERSON J L, EDNEY R J, WHELAN K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2012, 36(6): 503-516. |
48 | SHA S, LIANG J, CHEN M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J]. Aliment Pharmacol Ther, 2014, 39(10): 1003-1032. |
49 | WEINGARDEN A R, VAUGHN B P. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease[J]. Gut Microbes, 2017, 8(3): 238-252. |
50 | 李姗姗, 杨长青. 门静脉高压性肠病——一种不该忽视的门静脉高压并发症[J].临床肝胆病杂志,2022,38(6):1237-1241. |
[1] | Xiong LIN,Linghang QU,Jing XU,Chunlian LIU,Shuiqing LI,Yanju LIU. Improvement effects of Atractylodes rhizome oil and Atractylodes rhizome ethanol extract on ulcerative colitis model mice and comparison of their curative effects [J]. Journal of Jilin University(Medicine Edition), 2022, 48(5): 1247-1255. |
[2] | Qi LIU,Xin XU,Zhenggen WANG. Effect of calycosin on intestinal mucosal barrier function in cirrhosis rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 391-398. |
[3] | . Research progress in application of electronic nose in diagnosis of intestinal disease [J]. Journal of Jilin University(Medicine Edition), 2020, 46(6): 1332-1337. |
[4] | LI Jia, YANG Luoluo, ZHOU Changli, HE Ping, SUN Xun, MENG Xiangwei. Analysis on risk factors related to incidence of patientswithcolorectal polyps [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 646-650. |
[5] | . Research progress in role of IL-10 cytokine family in intestinal fibrosis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 849-851. |
[6] | LIU Yang, LIU Zhi, LI Fenge, KONG Fanli. Therapeutic effect of mosapride citrate on gastrointestinal tract function disorder of patients with Parkinson's syndrome [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 125-129. |
[7] | LI Hui,ZHAO Li-jing,DU Yu,YANG Tie-zheng,LI Guo-feng,CHEN Liang,ZHI Chen-yang,LI Na,ZHOU Jian-hua. Therapeutic effect of suppository of Jiechang An combined with Shuxue Ning on rats with ulcerative colitis and their mechanisms [J]. Journal of Jilin University Medicine Edition, 2013, 39(3): 488-493. |
[8] | WANG Min, JI Fu-jian, JIN Hong-yong,CHEN Xue-bo, YU Jie, FANG Xue-dong. Analysis of clinico-pathologic features on |metastasis of |lymph nodes around rectum in patients with rectal carcinoma [J]. J4, 2011, 37(2): 345-350. |
[9] | WANG Zhe, JIANG Yi-Zhong, SONG Yang, ZHOU Chang-Yu. Changes of clotting function indexes in elder patients with ulcerative colitis and significances [J]. J4, 2009, 35(3): 553-555. |
[10] | CHEN Xi,YANG Shi-zhong,CHI Bao-rong. Reproduction of rat inflammatory bowel disease model and intervention effect of Changkangyin on it [J]. J4, 2008, 34(2): 262-265. |
[11] | YU Jin-hai,SOU Jian,LI You-zhu,WANG Zhong-yi,LIU Guo-hui,WANG Quan. Inhibitory effect of Fe3+-CMC on expressions of TGF-β and FGF [J]. J4, 2007, 33(6): 1026-1028. |
[12] | . Clinical application of nutrision in intestinal preparing before colonoscopy [J]. J4, 2005, 31(1): 142-143. |
[13] | . Clinical significances of mean platelet volume and D-dipolymerin patients with inflammatory bowel disease [J]. J4, 2004, 30(6): 947-948. |
[14] | . Clinical curative effects of ChangYanKang oral liquid for ulcerative colitis [J]. J4, 2004, 30(5): 785-786. |
[15] | LI Tiantian, YANG Lanlan, JIA Shengnan, JIN Zhenjing. A case report of diagnosis and treatment of abdominal cocoon and literature review [J]. Journal of Jilin University Medicine Edition, 2015, 41(01): 172-174. |